Drug Trial Radar · NCT03299244
Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT)
Last checked: Nov 20, 2026Latest source record: Apr 30, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
637
Actual
Start
May 15, 2018
Primary completion
Apr 8, 2020
Study completion Apr 8, 2020
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Oct 3, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective is to demonstrate that treatment with etelcalcetide (AMG 416) is not inferior to treatment with cinacalcet for lowering serum intact parathyroid hormone (PTH) levels by \> 30% from baseline among participants with chronic kidney disease (CKD) and secondary hyperparathyroidism (SHPT) who require management with hemodialysis.
Conditions
- Secondary Hyperparathyroidism
- Chronic Kidney Disease
Interventions
EtelcalcetideDrug
Administered intravenously three times per week.
CinacalcetDrug
Cinacalcet administered orally once a day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With > 30% Reduction From Baseline in Mean Predialysis Intact Parathyroid Hormone During the Efficacy Assessment Phase - Non-inferiority AnalysisTime frame: Baseline and the efficacy assessment phase (EAP; defined as weeks 20 to 27, inclusive).
Locations
90 sites in 6 countries. Site status is shown where the registry gives one.
Research Site
Beijing, Beijing Municipality, China
Research Site
Lanzhou, Gansu, China
Research Site
Guangzhou, Guangdong, China
Research Site
Guangzhou, Guangdong, China
Research Site
Guangzhou, Guangdong, China
Research Site
Guangzhou, Guangdong, China
Research Site
Guangzhou, Guangdong, China
Research Site
Shenzhen, Guangdong, China
Research Site
Zhanjiang, Guangdong, China
Research Site
Nanning, Guangxi, China
Research Site
Nanning, Guangxi, China
Research Site
Zhengzhou, Henan, China
Research Site
Zhengzhou, Henan, China
Research Site
Wuhan, Hubei, China
Research Site
Wuhan, Hubei, China
Research Site
Wuhan, Hubei, China
Research Site
Changsha, Hunan, China
Research Site
Changsha, Hunan, China
Research Site
Changzhou, Jiangsu, China
Research Site
Nanjing, Jiangsu, China
Research Site
Nanjing, Jiangsu, China
Research Site
Wuxi, Jiangsu, China
Research Site
Changchun, Jilin, China
Research Site
Changchun, Jilin, China
Research Site
Dalian, Liaoning, China
Research Site
Dalian, Liaoning, China
Research Site
Dalian, Liaoning, China
Research Site
Shenyang, Liaoning, China
Research Site
Shenyang, Liaoning, China
Research Site
Xi'an, Shaanxi, China
Research Site
Qingdao, Shandong, China
Research Site
Shanghai, Shanghai Municipality, China
Research Site
Shanghai, Shanghai Municipality, China
Research Site
Shanghai, Shanghai Municipality, China
Research Site
Shanghai, Shanghai Municipality, China
Research Site
Taiyuan, Shanxi, China
Research Site
Chengdu, Sichuan, China
Research Site
Chengdu, Sichuan, China
Research Site
Tianjin, Tianjin Municipality, China
Research Site
Tianjin, Tianjin Municipality, China
Showing 40 of 90 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.